Viabahn球囊扩张式覆膜支架治疗髂动脉闭塞性病变的三年随访结果
VBX FLEX前瞻性多中心单臂研究纳入134例主髂动脉闭塞性病变患者,共治疗213处病变并植入234枚VBX支架。主要安全终点MAE复合发生率为2.3%,远低于17%的性能目标(p<0.001)。3年免于TLR为91.2%,9个月免于CD-TLR为98.6%,3年为98.1%,静息ABI较基线改善0.17±0.26(p<0.001)。
要点
- VBX支架3年MAE复合发生率2.3%,远低于17%性能目标(p<0.001)
- 3年免于TLR为91.2%,9个月免于CD-TLR为98.6%,3年为98.1%
- 3年静息ABI均值0.93±0.19,较基线改善0.17±0.26(p<0.001)
核心结论
- VBX球囊扩张式覆膜支架是主髂动脉闭塞性疾病稳健且持久的治疗选择,3年安全性和有效性结果持续。
研究设计与样本
- VBX FLEX研究为前瞻性、多中心、非随机、单臂临床研究(NCT02080871)。
- 共纳入134例患者(平均年龄66±9.5岁,79例男性),治疗213处病变,植入234枚支架。
- 主要安全终点为30天和9个月评估的主要不良事件(MAE)复合终点。
主要发现
- MAE复合发生率为2.3%,低于17%性能目标(p<0.001)。
- 1年Kaplan-Meier估计的一期通畅率为94.5%,一期辅助通畅率为99.0%。
- 按病变/血管计算的免于TLR在9个月为97.6%,3年为91.2%。
- 9个月免于CD-TLR为98.6%,3年为98.1%。
- 3年时82例(92.1%)Rutherford分级较基线改善至少1级,77例(86.5%)功能状态维持或改善。
关键数值与推荐
- MAE复合发生率2.3% vs 性能目标17%(p<0.001)。
- 1年一期通畅率94.5%,一期辅助通畅率99.0%。
- 免于TLR:9个月97.6%,3年91.2%;免于CD-TLR:9个月98.6%,3年98.1%。
- 3年静息ABI均值0.93±0.19,较基线改善0.17±0.26(p<0.001)。
临床怎么用
- 对于主髂动脉闭塞性病变(原发或再狭窄),VBX支架可作为安全有效的治疗选择,3年随访显示持续获益。
- 术后3年内靶病变血运重建率较低,CD-TLR尤其低,支持其持久性。
局限性
- 单臂、非随机设计,缺乏对照组。
- 134例中107例(80%)完成研究,存在随访丢失。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the midterm safety and effectiveness of the Gore Viabahn Balloon-Expandable Endoprosthesis (VBX Stent-Graft) in the treatment of patients with de novo or restenotic aortoiliac lesions. MATERIALS AND METHODS: The prospective, multicenter, nonrandomized, single-arm VBX FLEX clinical study (ClinicalTrials.gov identifier: NCT02080871) evaluated 134 patients (mean age 66±9.5 years; 79 men) up to 3 years after treatment with the VBX Stent-Graft. A total of 213 lesions were treated with 234 stent-grafts. The primary safety endpoint was a composite of major adverse events (MAEs), which were evaluated through 30 days and 9 months. Secondary outcomes collected through 3 years included freedom from target lesion revascularization (TLR), target vessel revascularization (TVR), clinically-driven TLR (CD-TLR), and CD-TVR as well as Rutherford category, resting ankle-brachial index (ABI), and functional status. A univariate analysis determined any correlation between baseline variables and TLR. RESULTS: The observed composite percentage of MAEs was 2.3%, well below the 17% performance goal (p<0.001). Of the 134 patients in the per protocol analysis, 107 (80%) completed the study. The 1-year Kaplan-Meier estimate of primary patency was 94.5% and primary assisted patency was 99.0%. The estimate of freedom from TLR per-lesion/vessel was 97.6% at 9 months and 91.2% at 3 years. The 9-month estimate of freedom from CD-TLR was 98.6% and the 3-year estimate was 98.1%. The 3-year mean resting ABI was 0.93±0.19, an improvement of 0.17±0.26 from baseline (p<0.001). At 3 years, 82 patients (92.1%) improved ≥1 Rutherford category from baseline, and 77 patients (86.5%) maintained or improved upon their baseline functional status. CONCLUSION: The VBX Stent-Graft is a robust and durable treatment option for aortoiliac occlusive disease as evidenced by the sustained 3-year safety and effectiveness outcomes.
引用
- Panneton JM, Bismuth J, Gray BH, et al. Three-Year Follow-up of Patients With Iliac Occlusive Disease Treated With the Viabahn Balloon- Expandable Endoprosthesis. J Endovasc Ther. 2020. PMID: 32329658. doi:10.1177/1526602820920569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。